A Non-interventional Study With Advanced Lung Squamous Cell Carcinoma

January 8, 2024 updated by: Yongchang Zhang, Hunan Province Tumor Hospital

A Non-interventional Study and Its Clinical Relevance With Advanced Lung Squamous Cell Carcinoma

This is a descriptive observational study, in which data are collected in an epidemiological fashion and prospective. This study does not intend to intervene the current medical practice of the recruited patients.

Study Overview

Status

Recruiting

Conditions

Advanced Lung Squamous Cell Carcinoma

Intervention / Treatment

Other: No treatment is included in this study

Study Type

Observational

Enrollment (Estimated)

130

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: Nong Yang, MD
Phone Number: +8613873123436 +8613055193557
Email: yangnong0217@163.com

Study Contact Backup

Name: Yongchang C Zhang, MD
Phone Number: 7+861383123436 +8613873123436
Email: zhangyongchang@csu.edu.cn

Study Locations

China
- Hunan
  - Changsha, Hunan, China, 410013
    - Recruiting
    - Yongchang Zhang
    - Contact:
      
      Yongchang Yongchang Zhang, MD
      
      Phone Number: +8613873123436 +8613873123436
      
      Email: zhangyongchang@csu.edu.cn

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

Adult
Older Adult

Accepts Healthy Volunteers

Sampling Method

Probability Sample

Study Population

advanced or metastatic (stage IV) lung squamous cell carcinoma

Description

Inclusion Criteria:

Patients must be ≥18 years.
Provision of fully informed consent prior to any study specific procedures.
Advanced or metastatic lung squamous cell carcinoma confirmed by histology or cytology.
According to the RECIST 1.1 standard, the patient must have at least one measurable lesion.

Exclusion Criteria:

None

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
progression-free survival Time Frame: 2 years	From registration onto that step until death, or censored at the date of last contact.	2 years
Overall survival Time Frame: 2 years	From registration onto that step until death, or censored at the date of last contact.	2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Hunan Province Tumor Hospital

Investigators

Principal Investigator: Yongchang Zhang, MD, Hunan Cancer Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 1, 2021

Primary Completion (Estimated)

December 31, 2024

Study Completion (Estimated)

December 31, 2025

Study Registration Dates

First Submitted

July 31, 2023

First Submitted That Met QC Criteria